|
|
Robert A. Rissman, Wayne W. Poon, Mathew Blurton-Jones, Salvatore Oddo, Reidun Torp, Michael P. Vitek, Frank M. LaFerla, Troy T. Rohn, Carl W. Cotman
J Clin Invest. 2004;
114(1):121
doi:10.1172/JCI20640
Abstract |
Full text
| PDF
| Supplemental material

N
eurofibrillary tangles (NFTs) are composed of abnormal aggregates of the cytoskeletal protein tau. Together with amyloid β (Aβ) plaques and neuronal and synaptic loss, NFTs constitute the primary pathological hallmarks of Alzheimer disease (AD). Recent evidence also suggests that caspases are activated early in the progression of AD and may play a role in neuronal loss and NFT pathology. Here we demonstrate that tau is cleaved at D421 (ΔTau) by executioner caspases. Following caspase-cleavage, ΔTau facilitates nucleation-dependent filament formation and readily adopts a conformational change recognized by the early pathological tau marker MC1. ΔTau can be phosphorylated by glycogen synthase kinase-3β and subsequently recognized by the NFT antibody PHF-1. In transgenic mice and AD brains, ΔTau associates with both early and late markers of NFTs and is correlated with cognitive decline. Additionally, ΔTau colocalizes with Aβ1–42 and is induced by Aβ1–42 in vitro. Collectively, our data imply that Aβ accumulation triggers caspase activation, leading to caspase-cleavage of tau, and that this is an early event that may precede hyperphosphorylation in the evolution of AD tangle pathology. These results suggest that therapeutics aimed at inhibiting tau caspase-cleavage may prove beneficial not only in preventing NFT formation, but also in slowing cognitive decline.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(14)
| Title and authors |
Publication |
Year |
Amyloid Precursor Protein Processing and Alzheimer's Disease
Richard J. O'Brien, Philip C. Wong
|
Annu. Rev. Neurosci.
|
2011 |
Yeast as a model system to study tau biology.
Ann De Vos, Jayamani Anandhakumar, Jeff Van den Brande, Mathias Verduyckt, Vanessa Franssens, Joris Winderickx, Erwin Swinnen
|
International Journal of Alzheimer's Disease
|
2011 |
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing.
Yipeng Wang, Marta Martinez-Vicente, Ulrike Krüger, Susmita Kaushik, Esther Wong, Eva-Maria Mandelkow, Ana Maria Cuervo, Eckhard Mandelkow
|
Human Molecular Genetics
|
2009 |
Structural Principles of Tau and the Paired Helical Filaments of Alzheimer?s Disease
Eckhard Mandelkow, Martin von Bergen, Jacek Biernat, Eva-Maria Mandelkow
|
Brain Pathology
|
2007 |
Phosphorylation and cleavage of tau in non-AD tauopathies
Angela L. Guillozet-Bongaarts, Kelly E. Glajch, Emilie G. Libson, Michael E. Cahill, Eileen Bigio, Robert W. Berry, Lester I. Binder
|
Acta Neuropathol
|
2007 |
Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau in situ: effects of GSK3β activation and caspase 3 cleavage
Wanjoo Chun, Geoffrey S. Waldo, Gail V. W. Johnson
|
Journal of Neurochemistry
|
2007 |
Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model.
Y P Wang, J Biernat, M Pickhardt, E Mandelkow, E-M Mandelkow
|
Proc. Natl. Acad. Sci. U.S.A.
|
2007 |
Conformational changes and cleavage of tau in Pick bodies parallel the early processing of tau found in Alzheimer pathology
S. Mondragón-Rodríguez, R. Mena, L. I. Binder, M. A. Smith, G. Perry, F. García-Sierra
|
Neuropathol Appl Neurobiol
|
2007 |
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo
Angela L. Guillozet-Bongaarts, Michael E. Cahill, Vincent L. Cryns, Matthew R. Reynolds, Robert W. Berry, Lester I. Binder
|
Journal of Neurochemistry
|
2006 |
Disease modifying therapy for AD?
Todd E. Golde
|
Journal of Neurochemistry
|
2006 |
|